201 related articles for article (PubMed ID: 12075825)
21. Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate.
Kang YS; Pardridge WM
J Pharmacol Exp Ther; 1994 Apr; 269(1):344-50. PubMed ID: 8169841
[TBL] [Abstract][Full Text] [Related]
22. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.
Wu D; Yang J; Pardridge WM
J Clin Invest; 1997 Oct; 100(7):1804-12. PubMed ID: 9312181
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors.
Kurihara A; Deguchi Y; Pardridge WM
Bioconjug Chem; 1999; 10(3):502-11. PubMed ID: 10346884
[TBL] [Abstract][Full Text] [Related]
24. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo.
Pardridge WM; Boado RJ; Kang YS
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5592-6. PubMed ID: 7777554
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery.
Bickel U; Yoshikawa T; Landaw EM; Faull KF; Pardridge WM
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2618-22. PubMed ID: 8385339
[TBL] [Abstract][Full Text] [Related]
26. Genetically engineered brain drug delivery vectors: cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody-streptavidin fusion gene and protein.
Li JY; Sugimura K; Boado RJ; Lee HJ; Zhang C; Duebel S; Pardridge WM
Protein Eng; 1999 Sep; 12(9):787-96. PubMed ID: 10506289
[TBL] [Abstract][Full Text] [Related]
27. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26.
Aktaş Y; Yemisci M; Andrieux K; Gürsoy RN; Alonso MJ; Fernandez-Megia E; Novoa-Carballal R; Quiñoá E; Riguera R; Sargon MF; Celik HH; Demir AS; Hincal AA; Dalkara T; Capan Y; Couvreur P
Bioconjug Chem; 2005; 16(6):1503-11. PubMed ID: 16287248
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution.
Lazarous DF; Shou M; Stiber JA; Dadhania DM; Thirumurti V; Hodge E; Unger EF
Cardiovasc Res; 1997 Oct; 36(1):78-85. PubMed ID: 9415275
[TBL] [Abstract][Full Text] [Related]
29. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat.
Moos T; Morgan EH
J Neurochem; 2001 Oct; 79(1):119-29. PubMed ID: 11595764
[TBL] [Abstract][Full Text] [Related]
30. Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS.
Boado RJ; Tsukamoto H; Pardridge WM
J Pharm Sci; 1998 Nov; 87(11):1308-15. PubMed ID: 9811482
[TBL] [Abstract][Full Text] [Related]
31. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease.
Zhang C; Chen J; Feng C; Shao X; Liu Q; Zhang Q; Pang Z; Jiang X
Int J Pharm; 2014 Jan; 461(1-2):192-202. PubMed ID: 24300213
[TBL] [Abstract][Full Text] [Related]
32. Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26.
Thom G; Burrell M; Haqqani AS; Yogi A; Lessard E; Brunette E; Delaney C; Baumann E; Callaghan D; Rodrigo N; Webster CI; Stanimirovic DB
Mol Pharm; 2018 Apr; 15(4):1420-1431. PubMed ID: 29485883
[TBL] [Abstract][Full Text] [Related]
33. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes.
Schnyder A; Krähenbühl S; Török M; Drewe J; Huwyler J
Biochem J; 2004 Jan; 377(Pt 1):61-7. PubMed ID: 14516278
[TBL] [Abstract][Full Text] [Related]
34. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system.
Cerletti A; Drewe J; Fricker G; Eberle AN; Huwyler J
J Drug Target; 2000; 8(6):435-46. PubMed ID: 11328669
[TBL] [Abstract][Full Text] [Related]
35. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo.
Pardridge WM; Buciak JL; Friden PM
J Pharmacol Exp Ther; 1991 Oct; 259(1):66-70. PubMed ID: 1920136
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate.
Kang YS; Boado RJ; Pardridge WM
Drug Metab Dispos; 1995 Jan; 23(1):55-9. PubMed ID: 7720525
[TBL] [Abstract][Full Text] [Related]
37. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor.
Zhang Y; Pardridge WM
J Pharmacol Exp Ther; 2005 Jun; 313(3):1075-81. PubMed ID: 15718287
[TBL] [Abstract][Full Text] [Related]
38. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity.
Haqqani AS; Thom G; Burrell M; Delaney CE; Brunette E; Baumann E; Sodja C; Jezierski A; Webster C; Stanimirovic DB
J Neurochem; 2018 Sep; 146(6):735-752. PubMed ID: 29877588
[TBL] [Abstract][Full Text] [Related]
39. Transport of [125I]transferrin through the rat blood-brain barrier.
Skarlatos S; Yoshikawa T; Pardridge WM
Brain Res; 1995 Jun; 683(2):164-71. PubMed ID: 7552351
[TBL] [Abstract][Full Text] [Related]
40. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26.
Pang Z; Lu W; Gao H; Hu K; Chen J; Zhang C; Gao X; Jiang X; Zhu C
J Control Release; 2008 Jun; 128(2):120-7. PubMed ID: 18436327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
